NCT02278133 - Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

June 23, 2017

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

WNT974

DRUG

LGX818

BIOLOGICAL

Cetuximab

Trial Locations (19)

3000

Array BioPharma Investigative Site, Leuven

3050

Array BioPharma Investigative Site, Parkville

10065

Memorial Sloan-Kettering Cancer Center (MSKCC) MSKCC (3), New York

13273

Array BioPharma Investigative Site, Marseille

20133

Array BioPharma Investigative Site, Milan

28041

Array BioPharma Investigative Site, Madrid

28050

Array BioPharma Investigative Site, Madrid

29425

Medical University of South Carolina Oncology Dept, Charleston

33076

Array BioPharma Investigative Site, Bordeaux

169610

Array BioPharma Investigative Site, Singapore

6423906

Array BioPharma Investigative Site, Tel Aviv

77030-4009

University of Texas/MD Anderson Cancer Center Onc. Dept,, Houston

53792-6164

University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc, Madison

T6G 1Z2

Array BioPharma Investigative Site, Edmonton

V5Z 4E6

Array BioPharma Investigative Site, Vancouver

M5G 2M9

Array BioPharma Investigative Site, Toronto

1066 CX

Array BioPharma Investigative Site, Amsterdam

08035

Array BioPharma Investigative Site, Barcelona

08907

Array BioPharma Investigative Site, L'Hospitalet de Llobregat